Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients

Acta Orthop Scand. 1991 Jun;62(3):226-9. doi: 10.3109/17453679108993597.

Abstract

The effect of naproxen on heterotopic ossification after total hip replacement was studied in a randomized, double-blind trial. Twenty-eight patients received 250 mg naproxen thrice daily for 4 weeks postoperatively starting on the morning of the operation while 27 control patients received a placebo. Three months after the operation, 13 patients in the control group had heterotopic ossification compared with 4 patients in the group that received naproxen; and after 1 year, the figures were 15 and 4, respectively (P less than 0.01). Three control patients had severe ossifications. We conclude that naproxen given for 4 weeks is sufficient to decrease the incidence of heterotopic ossification after cemented total hip replacement.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Double-Blind Method
  • Hip Prosthesis / adverse effects*
  • Humans
  • Middle Aged
  • Naproxen / administration & dosage
  • Naproxen / therapeutic use*
  • Ossification, Heterotopic / etiology
  • Ossification, Heterotopic / prevention & control*
  • Postoperative Care
  • Preoperative Care
  • Prospective Studies
  • Suppositories
  • Time Factors

Substances

  • Suppositories
  • Naproxen